Dapagliflozin vs Zibotentan + Dapagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT03036150 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)
Result source: NCT03036150
Zibotentan + Dapagliflozin
Developed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT06087835 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapagliflozin | Zibotentan + Dapagliflozin |
|---|---|---|
| Kidney composite outcome | 6.6% vs 11.3%−4.7 vs placeboNCT03036150 | —Trial running · NCT06087835 |
| UACR, % change | -22.4% vs -1.8%−20.6 vs placeboNCT025479359 other results
| —Trial running · NCT06087835 |
| eGFR slope | —Not posted · NCT05998837 | —Trial running · NCT06087835 |
| Haemoglobin, change | —Not posted · NCT05998837 | —Trial running · NCT06087835 |
Kidney composite outcome
- Dapagliflozin
- 6.6% vs 11.3%−4.7 vs placeboNCT03036150
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
UACR, % change
- Dapagliflozin
- -22.4% vs -1.8%−20.6 vs placeboNCT02547935
9 other results
- -39.1% vs -1.8% NCT02547935
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
eGFR slope
- Dapagliflozin
- —Not posted · NCT05998837
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
Haemoglobin, change
- Dapagliflozin
- —Not posted · NCT05998837
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dapagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapagliflozin |
|---|---|
| Dropout rate | —10 mga NCT03036150 · Phase 3 show 10 more results0.5%Dapagliflozin NCT03036150 · Phase 3 5.5%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 3.2%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 17.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 25%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 20.7%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 9.9%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mga NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 —10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence —10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 2.9%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 8.3%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3.9%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 29.5%10 mga NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 8.3%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 7.9%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 12.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 5.9%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.6%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 1.9%10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mga nasopharyngitis 4.3% (placebo 3.8%) urinary tract infection 3.6% (placebo 3.7%) hypoglycaemia 3.4% (placebo 3.3%) NCT03036150 · Phase 3 show 9 more results10 mg nasopharyngitis 6.9% (placebo 4.1%) influenza 5.5% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence 10 mg + 2.5 mg nasopharyngitis 6.6% (placebo 4.1%) influenza 1.3% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 10 mg hyperkalaemia 9.1% (placebo 0%) urinary tract infection 9.1% (placebo 0%) fall 6.1% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence 150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 1.5 mg brain natriuretic peptide increased 5% (placebo 0.6%) headache 4.5% (placebo 1.1%) metabolic acidosis 3.9% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 0.25 mg headache 6.6% (placebo 1.1%) hypertension 5.5% (placebo 0.6%) metabolic acidosis 5.5% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 10 mg any adverse event 32.1% (placebo 25%) NCT03190694 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 1 more result
show 9 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Zibotentan + Dapagliflozin's landscape